Bivatuzumab mertansine

{{Short description|Chemical compound}}

{{one source|date=August 2014}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 447729255

| image = Mertansine mab structure.svg

| type = mab

| mab_type = mab

| source = zu/o

| target = CD44 v6

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number =

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.{{cite journal | vauthors = Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA | display-authors = 6 | title = A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus | journal = Clinical Cancer Research | volume = 12 | issue = 20 Pt 1 | pages = 6064–72 | date = October 2006 | pmid = 17062682 | doi = 10.1158/1078-0432.CCR-06-0910 | doi-access = free }}